50 patient data show very significant improvement in OS and PFS in L2 setting,FDA has seen the data and encouraged CMRX to file for priority review, even if P3 in L1 setting fails very unlikely drug gets pulled from L2 setting, 800M in peak sales - what’s the bear case for $cmrx?
#cmrx